Phibro Animal Health (NASDAQ:PAHC) Issues Earnings Results, Beats Estimates By $0.14 EPS

Phibro Animal Health (NASDAQ:PAHC) released its quarterly earnings data on Wednesday. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.14, FiscalAI reports. The business had revenue of $396.75 million for the quarter, compared to the consensus estimate of $381.18 million. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%. Phibro Animal Health updated its FY 2027 guidance to 3.410-3.590 EPS.

Phibro Animal Health Trading Up 0.4%

PAHC stock traded up $0.16 during trading on Wednesday, reaching $36.09. The company had a trading volume of 287,583 shares, compared to its average volume of 295,650. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. Phibro Animal Health has a 52 week low of $28.25 and a 52 week high of $60.08. The business has a 50 day moving average of $33.84 and a 200 day moving average of $42.54. The company has a market cap of $1.46 billion, a P/E ratio of 15.49, a PEG ratio of 0.50 and a beta of 0.46.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 2nd. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. Phibro Animal Health’s payout ratio is currently 20.60%.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several research analyst reports. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lowered their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Finally, Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $42.50.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. iSAM Funds UK Ltd bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $61,000. C M Bidwell & Associates Ltd. raised its holdings in Phibro Animal Health by 1,756.5% in the fourth quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock worth $80,000 after purchasing an additional 2,020 shares in the last quarter. Advisory Services Network LLC bought a new position in Phibro Animal Health in the third quarter worth $96,000. EverSource Wealth Advisors LLC lifted its position in Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Phibro Animal Health by 768.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after buying an additional 4,079 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.